NEW YORK (GenomeWeb) – The US Food and Drug Administration announced on Friday it has completed the de novo premarket review and cleared for marketing Meridian Bioscience's cytomegalovirus assay for newborns called the Alethia CMV Assay Test System.

The Alethia brand is the new name for Meridian's molecular test line, which was previously marketed under the Illumigene and Illumipro names. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.